Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
AIDS Behav ; 27(12): 3970-3980, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37318665

RESUMEN

We assessed the prevalence and correlates of alcohol use among 870 people who inject drugs living with HIV in Kenya, with attention toward (1) sexual and injecting risk behaviors for HIV transmission and (2) HIV care engagement. We defined heavy alcohol use as > 14 drinks/week for men and > 7 drinks/week for women, moderate alcohol use as any lesser but non-zero amount, and any alcohol use as either moderate or heavy use. Approximately 39% of participants reported any alcohol use and 15% heavy use. In multivariate analysis, any alcohol use compared to no use was associated with needle sharing, > 3 new sex partners in the past 3 months, being unaware of HIV status, never enrolling in HIV care, and not being on ART (all p < 0.05). Heavy alcohol use as compared to no use was associated with needle sharing (aOR = 2.72; 95% CI 1.43, 5.13), injection equipment sharing (aOR = 1.80; 95% CI 1.00, 3.16), > 3 new sex partners in the past 3 months (aOR = 1.99; 95% CI 1.12, 3.49), and being unaware of HIV status (aOR = 2.77; 95% CI 1.46, 5.19). There was no association between any measure of alcohol use and unsuppressed viral load. Alcohol use among people who inject drugs living with HIV may carry elevated risk of HIV transmission mediated by sexual and injecting practices and is associated with lower engagement in multiple stages of the HIV care cascade.

2.
BJOG ; 128(3): 552-562, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-32931087

RESUMEN

OBJECTIVE: To validate externally five approaches to predict ectopic pregnancy (EP) in pregnancies of unknown location (PUL): the M6P and M6NP risk models, the two-step triage strategy (2ST, which incorporates M6P), the M4 risk model, and beta human chorionic gonadotropin ratio cut-offs (BhCG-RC). DESIGN: Secondary analysis of a prospective cohort study. SETTING: Eight UK early pregnancy assessment units. POPULATION: Women presenting with a PUL and BhCG >25 IU/l. METHODS: Women were managed using the 2ST protocol: PUL were classified as low risk of EP if presenting progesterone ≤2 nmol/l; the remaining cases returned 2 days later for triage based on M6P. EP risk ≥5% was used to classify PUL as high risk. Missing values were imputed, and predictions for the five approaches were calculated post hoc. We meta-analysed centre-specific results. MAIN OUTCOME MEASURES: Discrimination, calibration and clinical utility (decision curve analysis) for predicting EP. RESULTS: Of 2899 eligible women, the primary analysis excluded 297 (10%) women who were lost to follow up. The area under the ROC curve for EP was 0.89 (95% CI 0.86-0.91) for M6P, 0.88 (0.86-0.90) for 2ST, 0.86 (0.83-0.88) for M6NP and 0.82 (0.78-0.85) for M4. Sensitivities for EP were 96% (M6P), 94% (2ST), 92% (N6NP), 80% (M4) and 58% (BhCG-RC); false-positive rates were 35%, 33%, 39%, 24% and 13%. M6P and 2ST had the best clinical utility and good overall calibration, with modest variability between centres. CONCLUSIONS: 2ST and M6P performed best for prediction and triage in PUL. TWEETABLE ABSTRACT: The M6 model, as part of a two-step triage strategy, is the best approach to characterise and triage PULs.


Asunto(s)
Pruebas de Embarazo/normas , Embarazo Ectópico/diagnóstico , Triaje/normas , Adulto , Calibración , Gonadotropina Coriónica Humana de Subunidad beta/análisis , Reacciones Falso Positivas , Femenino , Humanos , Valor Predictivo de las Pruebas , Embarazo , Pruebas de Embarazo/métodos , Estudios Prospectivos , Curva ROC , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Triaje/métodos
3.
Ultrasound Obstet Gynecol ; 55(1): 105-114, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31385381

RESUMEN

OBJECTIVE: The M6 risk-prediction model was published as part of a two-step protocol using an initial progesterone level of ≤ 2 nmol/L to identify probable failing pregnancies (Step 1) followed by the M6 model (Step 2). The M6 model has been shown to have good triage performance for stratifying women with a pregnancy of unknown location (PUL) as being at low or high risk of harboring an ectopic pregnancy (EP). This study validated the triage performance of the two-step protocol in clinical practice by evaluating the number of protocol-related adverse events and how effectively patients were triaged. METHODS: This was a prospective multicenter interventional study of 3272 women with a PUL, carried out between January 2015 and January 2017 in four district general hospitals and four university teaching hospitals in the UK. The final pregnancy outcome was defined as: a failed PUL (FPUL), an intrauterine pregnancy (IUP) or an EP (including persistent PUL (PPUL)). FPUL and IUP were grouped as low-risk and EP/PPUL as high-risk PUL. Serum progesterone and human chorionic gonadotropin (hCG) levels were measured at presentation in all patients. If the initial progesterone level was ≤ 2 nmol/L, patients were discharged and were asked to have a follow-up urine pregnancy test in 2 weeks to confirm a negative result. If the progesterone level was > 2 nmol/L or a measurement had not been taken, hCG level was measured again at 48 h and results were entered into the M6 model. Patients were managed according to the outcome predicted by the protocol. Those classified as 'low risk, probable FPUL' were advised to perform a urine pregnancy test in 2 weeks and those classified as 'low risk, probable IUP' were invited for a scan a week later. When a woman with a PUL was classified as high risk (i.e. risk of EP ≥ 5%) she was reviewed clinically within 48 h. One center used a progesterone cut-off of ≤ 10 nmol/L and its data were analyzed separately. If the recommended management protocol was not adhered to, this was recorded as a protocol deviation and classified as: unscheduled visit for clinician reason, unscheduled visit for patient reason or incorrect timing of blood test or ultrasound scan. The classifications outlined in the UK Good Clinical Practice (GCP) guidelines were used to evaluate the incidence of adverse events. Data were analyzed using descriptive statistics. RESULTS: Of the 3272 women with a PUL, 2625 were included in the final analysis (317 met the exclusion criteria or were lost to follow-up, while 330 were evaluated using a progesterone cut-off of ≤ 10 nmol/L). Initial progesterone results were available for 2392 (91.1%) patients. In Step 1, 407 (15.5%) patients were classified as low risk (progesterone ≤ 2 nmol/L), of whom seven (1.7%) were ultimately diagnosed with an EP. In 279 of the remaining 2218 women with a PUL, the M6 model was not applied owing to protocol deviation or because the outcome was already known (usually on the basis of an ultrasound scan) before a second hCG reading was taken; of these patients, 30 were diagnosed with an EP. In Step 2, 1038 women with a PUL were classified as low risk, of whom eight (0.8%) had a final outcome of EP. Of 901 women classified as high risk at Step 2, 275 (30.5%) had an EP. Therefore, 275/320 (85.9%) EPs were correctly classified as high risk. Overall, 1445/2625 PUL (55.0%) were classified as low risk, of which 15 (1.0%) were EP. None of these cases resulted in a ruptured EP or significant clinical harm. Sixty-two women participating in the study had an adverse event, but no woman had a serious adverse event as defined in the UK GCP guidelines. CONCLUSIONS: This study has shown that the two-step protocol incorporating the M6 model effectively triaged the majority of women with a PUL as being at low risk of an EP, minimizing the follow-up required for these patients after just two visits. There were few misclassified EPs and none of these women came to significant clinical harm or suffered a serious adverse clinical event. The two-step protocol incorporating the M6 model is an effective and clinically safe way of rationalizing the management of women with a PUL. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.


Asunto(s)
Embarazo Ectópico/diagnóstico , Diagnóstico Prenatal , Triaje , Adulto , Protocolos Clínicos , Técnicas de Apoyo para la Decisión , Árboles de Decisión , Inglaterra , Femenino , Humanos , Embarazo , Embarazo Ectópico/sangre , Embarazo Ectópico/terapia , Estudios Prospectivos
6.
Clin Exp Immunol ; 181(3): 451-6, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25739813

RESUMEN

HIV-infected children are less capable of mounting and maintaining protective humoral responses to vaccination against measles compared to HIV-uninfected children. This poses a public health challenge in countries with high HIV burdens. Administration of anti-retroviral therapy (ART) and revaccinating children against measles is one approach to increase measles immunity in HIV-infected children, yet it is not effective in all cases. Immune anergy and activation during HIV infection are factors that could influence responses to measles revaccination. We utilized a flow cytometry-based approach to examine whether T cell anergy and activation were associated with the maintenance of measles-specific immunoglobulin (Ig)G antibodies generated in response to measles revaccination in a cohort of HIV-infected children on ART in Nairobi, Kenya. Children who sustained measles-specific IgG for at least 1 year after revaccination displayed significantly lower programmed cell death 1 (PD-1) surface expression on CD8(+) T cells on a per-cell basis and exhibited less activated CD4(+) T cells compared to those unable to maintain detectable measles-specific antibodies. Children in both groups were similar in age and sex, CD4(+) T cell frequency, duration of ART treatment and HIV viral load at enrolment. These data suggest that aberrant T cell anergy and activation are associated with the impaired ability to sustain an antibody response to measles revaccination in HIV-infected children on ART.


Asunto(s)
Formación de Anticuerpos/inmunología , Infecciones por VIH/inmunología , Sarampión/inmunología , Linfocitos T/inmunología , Anticuerpos Antivirales/inmunología , Terapia Antirretroviral Altamente Activa , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/metabolismo , Linfocitos T CD4-Positivos/virología , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/metabolismo , Linfocitos T CD8-positivos/virología , Niño , Preescolar , Anergia Clonal/inmunología , Femenino , Citometría de Flujo , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , Humanos , Inmunización Secundaria/métodos , Inmunoglobulina G/inmunología , Kenia , Activación de Linfocitos/inmunología , Masculino , Sarampión/prevención & control , Receptor de Muerte Celular Programada 1/inmunología , Receptor de Muerte Celular Programada 1/metabolismo , Carga Viral/inmunología
7.
AIDS ; 11(7): 903-9, 1997 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-9189216

RESUMEN

OBJECTIVE: To establish a cohort of high-risk individuals suitable for HIV-prevention trials, and to measure changes in sexual behaviour and sexually transmitted disease (STD) incidence after a behavioural intervention. DESIGN: Prospective cohort study in trucking company depots in Mombasa, Kenya. PARTICIPANTS: A total of 556 male HIV-seronegative employees of trucking companies. INTERVENTIONS: HIV serological testing, individual counselling, condom promotion, STD diagnosis and management. MAIN OUTCOME MEASURES: Sexual risk behaviour and symptomatic STD incidence. RESULTS: Using time-trend modelling, significant declines in self-reported high-risk sexual behaviour were demonstrated during a 1-year follow-up. The percentage of men reporting any extramarital sex during the 3-month period prior to a follow-up visit decreased from 49% durig the first quarter of follow-up to 36% during the last quarter (P < 0.001). The decline in reported female sex worker contact was from 12% to 6% (P = 0.001). Approximately 30% of men reported consistent condom use during extramarital sex and this percentage remained unchanged during the study period. The incidence of STD declined from 34 per 100 person years (PY) during the first quarter to 10 per 100 PY during the last quarter (P = 0.001). Significant reductions in gonorrhoea (15 to five cases per 100 PY, P = 0.04), non-gonococcal urethritis (10 to two cases per 100 PY, P = 0.05), and genital ulcer disease (nine to two cases per 100 PY, P = 0.02) were observed. CONCLUSIONS: Among truck company workers who participated in a cohort study in Mombasa, Kenya, there was a significant decrease in sex with high-risk partners, but no change in condom use. The change in heterosexual risk behaviour was accompanied by a significant decrease in incidence of gonorrhoea, non-gonococcal urethritis, and genital ulcer disease.


PIP: 556 male HIV-seronegative male employees of trucking companies in Mombasa, Kenya, were exposed to HIV serological testing, individual counseling, condom promotion, and sexually transmitted disease (STD) diagnosis and management, and returned for at least one follow-up visit in a prospective study to measure changes in sexual behavior and STD incidence after the intervention. There was a significant decrease in sex with high-risk partners over the 1-year period of follow-up, but no change in condom use among study participants; 30% of men reported consistent condom use during extramarital sex throughout the study period. The change in heterosexual risk behavior was accompanied by a significant decrease in the incidence of gonorrhea, nongonococcal urethritis, and genital ulcer disease. The percentage of men reporting extramarital sex decreased from 49% to 36%, while contact with female prostitutes declined from 12% to 6%.


Asunto(s)
Conducción de Automóvil , Educación en Salud , Conducta Sexual , Enfermedades de Transmisión Sexual/epidemiología , Adolescente , Adulto , Chancroide/epidemiología , Infecciones por Chlamydia/epidemiología , Estudios de Cohortes , Condones/estadística & datos numéricos , Femenino , Estudios de Seguimiento , Gonorrea/epidemiología , Seronegatividad para VIH , Humanos , Incidencia , Kenia/epidemiología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Asunción de Riesgos , Enfermedades de Transmisión Sexual/prevención & control
8.
Ophthalmic Genet ; 22(3): 163-9, 2001 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11559858

RESUMEN

PURPOSE: To report a new phenotype in retinitis pigmentosa (RP) patients with CRB1 mutations at the RP12 locus. PATIENTS: Thirty-seven patients from two Pakistani families with severe retinitis pigmentosa. METHODS: Samples were screened with single-strand conformation polymorphism analysis followed by DNA sequencing of the coding sequence of the CRB1 gene. RESULTS: Two novel CRB1 mutations were discovered. No patients had evidence of preservation of the para-arteriolar retinal pigment epithelium (PPRPE) that has been previously reported in all cases of RP associated with CRB1 mutations. CONCLUSIONS: Patients with severe autosomal recessive (or simplex) RP who lack the finding of PPRPE should not be excluded from molecular analysis of CRB1 purely because they lack the clinical feature of PPRPE. This report illustrates that RP at the RP12 locus is not clinically uniform. The absence of PPRPE cannot be used to exclude CRB1 as a potential molecular explanation for RP.


Asunto(s)
Proteínas de Drosophila , Proteínas de la Membrana/genética , Mutación/genética , Retinitis Pigmentosa/genética , Adolescente , Adulto , Edad de Inicio , Arteriolas/patología , Análisis Mutacional de ADN , Femenino , Angiografía con Fluoresceína , Genotipo , Humanos , Masculino , Linaje , Epitelio Pigmentado Ocular/patología , Reacción en Cadena de la Polimerasa , Polimorfismo Conformacional Retorcido-Simple , Retinitis Pigmentosa/patología
15.
Homeopathy ; 93(2): 67-70, 2004 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15139089

RESUMEN

This study aimed to evaluate the effect of a GP-led practice-based homeopathy service on symptoms, activity, wellbeing, general practice consultation rate and the use of conventional medications. Data were collected for 97 consecutive patients referred to a homeopathy service between 1 July 2002 and 23 January 2003. Self-rated symptom severity, activity limitation and wellbeing were scored on a seven-point scale at initial homeopathic consultation and via postal questionnaire at a mean follow-up time of 134 days. Primary symptoms improved by a mean of 2.49 points (95% confidence interval (CI) 2.08-2.90; P < 0.0001); secondary symptoms by 2.49 points (95% CI 2.00-2.98; P < 0.0001); ability to undertake activity by 2.43 points (95% CI 1.95-2.91; P < 0.0001) and wellbeing by 1.41 points (95% CI 1.02-1.80; P < 0.0001). Following use of the homeopathy service the mean 6-month general practice consultation rate decreased by 1.18 consultations per patient (95% CI 0.40-1.99; P = 0.004). Fifty-seven per cent of patients reduced or stopped taking their conventional medication, saving 2,807.30 Pounds per year. The main limitation of this study is the absence of a control group. The findings warrant further research including controlled studies and economic analysis.


Asunto(s)
Costos de los Medicamentos/estadística & datos numéricos , Medicina Familiar y Comunitaria/estadística & datos numéricos , Homeopatía/estadística & datos numéricos , Satisfacción del Paciente/estadística & datos numéricos , Derivación y Consulta/estadística & datos numéricos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Intervalos de Confianza , Ahorro de Costo , Costos y Análisis de Costo , Medicina Familiar y Comunitaria/economía , Medicina Familiar y Comunitaria/normas , Femenino , Homeopatía/economía , Homeopatía/normas , Humanos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Proyectos Piloto , Calidad de Vida , Reino Unido
16.
J Virol ; 69(12): 8118-22, 1995 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-7494333

RESUMEN

In order to develop a human immunodeficiency virus type 1 vaccine with global efficacy, it is important to evaluate the virus populations that are transmitted to individuals living in high-incidence areas. To determine the nature of the human immunodeficiency virus type 1 population transmitted to women during heterosexual contact, we examined the diversity of the proviral envelope gene in infected cells in both genital secretions and peripheral blood from six recently seroconverted Kenyan women. Heterogeneous virus populations were present in cervical secretions and/or peripheral blood shortly after seroconversion for five of six infected individuals, and tissue-specific variants were identified in several cases.


PIP: The HIV-1 population in an infected individual often includes a diverse mix of variants distinguished mainly by differences in the extracellular envelope glycoprotein. Some variants may be favored for cell- and tissue-specific replication. In order to develop a HIV-1 vaccine which will be effective worldwide, researchers need to evaluate the virus populations which are transmitted to individuals living in high-incidence areas. The authors examined the diversity of the proviral envelope gene in infected cells in the genital secretions and peripheral blood of six recently seroconverted Kenyan female prostitutes in the attempt to determine the nature of the HIV-1 population transmitted to women during heterosexual contact. Heterogeneous virus populations were present in cervical secretions and/or peripheral blood shortly after seroconversion for five of the six women, and tissue-specific variants were identified in several cases. Study findings suggest that virus heterogeneity in the cohort was due to the transmission of multiple HIV-1 genotypes.


Asunto(s)
Cuello del Útero/virología , ADN Viral/análisis , Productos del Gen env/genética , Variación Genética , Seropositividad para VIH/virología , VIH-1/genética , VIH-1/aislamiento & purificación , Filogenia , Vacunas contra el SIDA , Secuencia de Aminoácidos , Secuencia de Bases , Cuello del Útero/metabolismo , Estudios de Cohortes , Cartilla de ADN , ADN Viral/genética , Femenino , Productos del Gen env/química , Genes env , Humanos , Kenia , Linfocitos/virología , Masculino , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa , Provirus/genética , Provirus/aislamiento & purificación , Homología de Secuencia de Aminoácido , Trabajo Sexual
17.
J Infect Dis ; 183(7): 1017-22, 2001 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-11237825

RESUMEN

To assess the effect of treatment of vaginal infections on vaginal shedding of cell-free human immunodeficiency virus type 1 (HIV-1) and HIV-1-infected cells, HIV-1-seropositive women were examined before and after treatment of Candida vulvovaginitis, Trichomonas vaginitis, and bacterial vaginosis. For Candida (n=98), vaginal HIV-1 RNA decreased from 3.36 to 2.86 log(10) copies/swab (P<.001), as did the prevalence of HIV-1 DNA (36% to 17%; odds ratio [OR], 2.8; 95% confidence interval [CI], 1.3-6.5). For Trichomonas vaginitis (n=55), HIV-1 RNA decreased from 3.67 to 3.05 log(10) copies/swab (P<.001), but the prevalence of HIV-1 DNA remained unchanged (22%-25%; OR, 0.8; 95% CI, 0.3-2.2). For bacterial vaginosis (n=73), neither the shedding of HIV-1 RNA (from 3.11 to 2.90 log(10) copies/swab; P=.14) nor the prevalence of DNA (from 21% to 23%; OR, 0.8; 95% CI, 0.3-2.0) changed. Vaginal HIV-1 decreased 3.2- and 4.2-fold after treating Candida and Trichomonas, respectively. These data suggest that HIV-1 transmission intervention strategies that incorporate diagnosis and treatment of these prevalent infections warrant evaluation.


Asunto(s)
Antibacterianos/uso terapéutico , Antitricomonas/uso terapéutico , Infecciones por VIH/virología , Seropositividad para VIH/virología , VIH-1/aislamiento & purificación , Vagina/virología , Vaginitis/tratamiento farmacológico , Esparcimiento de Virus/efectos de los fármacos , Adulto , Candidiasis/complicaciones , Candidiasis/tratamiento farmacológico , ADN Viral/análisis , Regulación hacia Abajo , Femenino , Infecciones por VIH/complicaciones , Infecciones por VIH/transmisión , Seropositividad para VIH/complicaciones , VIH-1/genética , Humanos , Metronidazol/uso terapéutico , Nistatina/uso terapéutico , Oportunidad Relativa , Estudios Prospectivos , ARN Viral/análisis , Vaginitis por Trichomonas/complicaciones , Vaginitis por Trichomonas/tratamiento farmacológico , Vagina/patología , Vaginitis/complicaciones , Vaginitis/microbiología , Vaginosis Bacteriana/complicaciones , Vaginosis Bacteriana/tratamiento farmacológico
18.
Clin Diagn Lab Immunol ; 8(2): 346-8, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11238219

RESUMEN

This study was performed to evaluate the performance of a saliva collection device (OmniSal) and an enzyme-linked immunoassay (EIA) designed for use on serum samples (Detect HIV1/2) to detect human immunodeficiency virus type 1 (HIV-1) antibodies in the saliva of high-risk women in Mombasa, Kenya. The results of the saliva assay were compared to a "gold standard" of a double-EIA testing algorithm performed on serum. Individuals were considered HIV-1 seropositive if their serum tested positive for antibodies to HIV-1 by two different EIAs. The commercial serum-based EIA was modified to test the saliva samples by altering the dilution and lowering the cutoff point of the assay. Using the saliva sample, the EIA correctly identified 102 of the 103 seropositive individuals, yielding a sensitivity of 99% (95% confidence interval [CI], 94 to 100%), and 96 of the 96 seronegative individuals, yielding a specificity of 100% (95% CI, 95 to 100%). In this high-risk population, the positive predictive value of the assay was 100% and the negative predictive value was 99%. We conclude that HIV-1 antibody testing of saliva samples collected with this device and tested by this EIA is of sufficient sensitivity and specificity to make this protocol useful in epidemiological studies.


Asunto(s)
Ensayo de Inmunoadsorción Enzimática/normas , Anticuerpos Anti-VIH/análisis , Infecciones por VIH/diagnóstico , VIH-1/aislamiento & purificación , Saliva/inmunología , Ensayo de Inmunoadsorción Enzimática/métodos , Femenino , Infecciones por VIH/epidemiología , Infecciones por VIH/inmunología , VIH-1/inmunología , Humanos , Inmunoglobulina G/análisis , Cooperación del Paciente , Reproducibilidad de los Resultados , Saliva/virología , Sensibilidad y Especificidad , Trabajo Sexual
19.
Am J Obstet Gynecol ; 183(4): 948-55, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11035345

RESUMEN

OBJECTIVE: Our purpose was to evaluate the frequency and patterns of the shedding of herpes simplex virus and cytomegalovirus in the female genital tract throughout the menstrual cycle. STUDY DESIGN: Seventeen women, all seropositive for herpes simplex virus types 1 and 2, cytomegalovirus, and human immunodeficiency virus type 1, underwent daily evaluation of cervical viral shedding for the duration of 1 menstrual cycle (21-31 visits per woman). Serum estradiol and progesterone levels were monitored 3 times weekly. RESULTS: Overall, herpes simplex virus deoxyribonucleic acid was detected in 43 (10%) of 450 cervical swabs, and cytomegalovirus deoxyribonucleic acid was detected in 232 (52%) of 450 cervical swabs. For individual women there was considerable variability in the percentage of days on which virus was detected, ranging from 0% to 33% for herpes simplex virus and from 20% to 97% for cytomegalovirus. Shedding of herpes simplex virus did not vary significantly with menstrual cycle; however, shedding of cytomegalovirus was significantly more frequent in the luteal phase (odds ratio, 1.9; 95% confidence interval, 1.1-3.4). A CD4(+) lymphocyte count <200/microL was associated with increased frequency of the detection of herpes simplex virus (odds ratio, 5.7; 95% confidence interval, 1.1-29.4). CONCLUSIONS: Asymptomatic cervical shedding of both herpes simplex virus and cytomegalovirus occurs very frequently in women infected with human immunodeficiency virus type 1. The risk of transmitting these viruses to sexual partners and neonates may be higher than previously recognized.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/virología , Cuello del Útero/virología , Citomegalovirus/fisiología , VIH-1 , Ciclo Menstrual , Simplexvirus/fisiología , Esparcimiento de Virus , Síndrome de Inmunodeficiencia Adquirida/fisiopatología , Adulto , Cuello del Útero/química , Citomegalovirus/genética , ADN Viral/análisis , Femenino , Humanos , Simplexvirus/genética
20.
J Infect Dis ; 175(4): 833-8, 1997 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-9086138

RESUMEN

Transport workers (n = 504) in Mombasa, Kenya, were screened for urethral infection by history, clinical examination, and laboratory testing of urethral swabs and first-catch urine specimens. The prevalence of Neisseria gonorrhoeae was 3.4%, Chlamydia trachomatis, 3.6%, and Trichomonas vaginalis, 6.0%; more than two-thirds of infections were asymptomatic. A complaint of urethral discharge, dysuria, or both was twice as sensitive as the sign of discharge on physical examination (34.5% vs. 15.5%) in identifying infection. A positive leukocyte esterase dipstick (LED) test on urine predicted infection with a sensitivity of 95.0% and a specificity of 59.3% in symptomatic men and with a sensitivity of 55.3% and a specificity of 82.8% in asymptomatic men. Demographic and behavioral factors were not independent predictors of infection. In resource-poor settings with high prevalences of urethral infection, an effective screening and management strategy would be to treat symptomatic men, as well as asymptomatic men with a positive LED test, for all three infections.


Asunto(s)
Infecciones Bacterianas/epidemiología , Enfermedades Uretrales/epidemiología , Adolescente , Adulto , África/epidemiología , Infecciones Bacterianas/diagnóstico , Infecciones Bacterianas/terapia , Infecciones por Chlamydia/diagnóstico , Infecciones por Chlamydia/epidemiología , Infecciones por Chlamydia/terapia , Femenino , Gonorrea/diagnóstico , Gonorrea/epidemiología , Gonorrea/terapia , Humanos , Masculino , Persona de Mediana Edad , Vaginitis por Trichomonas/diagnóstico , Vaginitis por Trichomonas/epidemiología , Vaginitis por Trichomonas/terapia , Enfermedades Uretrales/diagnóstico , Enfermedades Uretrales/terapia , Lugar de Trabajo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA